TriangleBotensilimab (NCT07735624)
Botensilimab trial for Early Rectal Cancer (NCT07735624). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated stage I rectal cancer, T1–T2 N0 M0, microsatellite-stable and mismatch-repair-proficient. Patients must be suitable for standard treatment options.
The idea: botensilimab and balstilimab block immune brakes CTLA-4 and PD-1. Patients receive one 75-milligram botensilimab infusion and 240-milligram balstilimab infusions every two weeks for up to six months. Response determines further care. Selected responders may enter surveillance; near-complete responses require local excision confirming complete pathological response. Residual or progressing cancer receives standard care.
This phase 2 study plans 16 patients. Dana-Farber sponsors two recruiting sites in Boston.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.